Several studies, including one by the Congressional Advisory Committee, evaluate the reduction in costs and the increase in access to biologic treatments when biosimilar medicines are introduced.
Industry news
Several studies, including one by the Congressional Advisory Committee, evaluate the reduction in costs and the increase in access to biologic treatments when biosimilar medicines are introduced.
recently published
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.